Poolbeg Pharma’s (POLB) House Stock Rating Reiterated at Shore Capital

Shore Capital reaffirmed their house stock rating on shares of Poolbeg Pharma (LON:POLB) in a research report report published on Wednesday, MarketBeat Ratings reports.

Poolbeg Pharma Trading Down 2.4%

LON:POLB opened at GBX 4.30 on Wednesday. The stock has a 50 day moving average of GBX 4.13 and a 200-day moving average of GBX 3.70. The firm has a market capitalization of £29.95 million, a PE ratio of -3.77 and a beta of 2.11. Poolbeg Pharma has a 52 week low of GBX 2.25 and a 52 week high of GBX 5.40.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.